Bladder Cancer

Stay updated with the latest content from our #BladderCancer journal by signing up to get news direct to your inbox. Go to: tiny.cc/BLCsignup Keep informed about new articles, challenging cases, reviews, & other features like our Clinical Trials Corner! #GoldOpenAccess

RESEARCH REPORT: BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis by Zine-Eddine KHENE et al. journals.sagepub.com/doi/10.1177/23… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

SHORT COMMUNICATION: Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies by Yelba Castellon-Lopez and Patricia Thompson. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

The First Systematic Review and Meta-Analysis of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors in Urothelial Cancer: Efficacy, Clinical Use and Future Applications by @mjmoussa_ et al. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

REVIEW: Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: evaluating treatment outcomes by Vera Rutten et al. journals.sagepub.com/doi/10.1177/23… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

⚡️ On @EUplatinum - Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure. - Feasible administration with negligible toxicity. - Encouraging efficacy as a localized immune checkpoint inhibitor. - Intravesical delivery may surpass systemic approaches. #BladderCancer #Immunotherapy @OncoAlert sciencedirect.com/science/articl…

🔥NOW in @BladderCaJrnl of @BladderCancerUS👉Can Combining ICIs w/ Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer? @OAlhalabiMD @MDAndersonNews 1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed. Better patient selection🔑?

RESEARCH REPORT: North American Study and Meta-analysis Evaluating Performance of Bladder EpiCheck®, a FDA cleared test, in Non-Muscle Invasive Bladder Cancer Recurrence by Neil Fleshner et al. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Research Report: Repeat TURBT in large volume HG Ta NMIBC treated with induction BCG therapy was not associated with improved high-risk recurrence-free survival. @durant_adri et al. journals.sagepub.com/doi/full/10.11…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1

RESEARCH REPORT: Effectiveness of prolonged antibiotic prophylaxis in radical cystectomy: preliminary analysis of the MACS randomized clinical trial by Mariya Berkut et al. pmc.ncbi.nlm.nih.gov/articles/PMC11…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1

SHORT COMMUNICATION: Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists by Ivy Beeren et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by @RonaldChenMD, @slernerbcmedu1, @sonpavde, @HimanshuNagarMD, @Parminder1699 et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu

NEW REVIEW focusing on ctDNA👉Perioperative use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now👈by @DrTylerStewart et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @DrChoueiri @FaltasLab @slernerbcmedu1

New Research Report: A molecular urine assay to detect recurrences during surveillance of high-risk non-muscle invasive bladder cancer by @FCdeJong, @JoepJdeJong, et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Happy to present the latest review in Bladder Cancer by @SandeepGurramMD and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing ✅Rationale for devices ✅Devices available ✅Mechanisms ✅Efficacy ✅Safety ✅Future Studies

⚡️ Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial #BladderCancer @docpriyamvada @VedangMurthy sciencedirect.com/science/articl…

In @Nature: Full text article "Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer." Click here to read it: nature.com/articles/s4159…

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. 👇

⚡️ On @EUplatinum - Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma #BladderCancer @IverNordentoft @SiaLindskrog europeanurology.com/article/S0302-…

⚡️ Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy #BladderCancer @mjmoussa_ @OAlhalabiMD @PavlosMsaouel ⁩ @DocMattCampbell mdpi.com/1718-7729/31/6… ⁩ ⁦

Out now @EUplatinum - our review of FGFR inhibition in #bladdercancer covering: 👉MoA of receptor mediated signaling 👉Incidence in UC 👉Impact on TiME 👉Clinical trials and results 👉Possible mech of resistance Prelude to #PrecisionMedicine in UC authors.elsevier.com/a/1js9L14kplyz…